- Home
- SFST vs AVIR Comparison
SFST vs AVIR Comparison
Compare SFST & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- AVIR
- Stock Information
- Founded
- SFST 1999
- AVIR 2012
- Country
- SFST United States
- AVIR United States
- Employees
- SFST N/A
- AVIR N/A
- Industry
- SFST Major Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- SFST Finance
- AVIR Health Care
- Exchange
- SFST Nasdaq
- AVIR Nasdaq
- Market Cap
- SFST 335.4M
- AVIR 290.4M
- IPO Year
- SFST 1999
- AVIR 2020
- Fundamental
- Price
- SFST $41.82
- AVIR $3.20
- Analyst Decision
- SFST Buy
- AVIR Hold
- Analyst Count
- SFST 1
- AVIR 1
- Target Price
- SFST $51.00
- AVIR $6.00
- AVG Volume (30 Days)
- SFST 17.3K
- AVIR 436.8K
- Earning Date
- SFST 10-21-2025
- AVIR 11-07-2025
- Dividend Yield
- SFST N/A
- AVIR N/A
- EPS Growth
- SFST 58.48
- AVIR N/A
- EPS
- SFST 2.69
- AVIR N/A
- Revenue
- SFST $102,878,000.00
- AVIR N/A
- Revenue This Year
- SFST $13.23
- AVIR N/A
- Revenue Next Year
- SFST $17.49
- AVIR N/A
- P/E Ratio
- SFST $15.80
- AVIR N/A
- Revenue Growth
- SFST 15.60
- AVIR N/A
- 52 Week Low
- SFST $29.14
- AVIR $2.46
- 52 Week High
- SFST $46.40
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- SFST 43.60
- AVIR 56.66
- Support Level
- SFST $40.90
- AVIR $3.04
- Resistance Level
- SFST $42.88
- AVIR $3.30
- Average True Range (ATR)
- SFST 0.96
- AVIR 0.12
- MACD
- SFST -0.12
- AVIR 0.04
- Stochastic Oscillator
- SFST 30.11
- AVIR 83.70
About SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).